Download CpG island methylator phenotype of non

CpG island methylator phenotype of non-small cell lung cancer
Speaker : Cheng-Hung Tsai
Adviser: Michael Chen
Date: 2014.9.26
Lung cancer is the leading cause of cancer-related deaths in the world. Nonsmall cell lung cancer (NSCLC) comprises the majority of lung cancer and has an
increasing incidence and mortality in the last two decades. Aberrant DNA
methylation is a common phenomenon in human cancer. Synchronous methylation
of multiple genes, which was defined as a CpG island methylator phenotype (CIMP),
has been reported in various types of cancers, including NSCLC.
The aims of this study were to investigate the methylation profiles of non-small
cell lung cancer (NSCLC) in the Central Taiwan population. Ten tumor suppressor
genes (TSGs) (APC, RassF1A, ANGPTL4, FBXO32, RunX1T1, SFRP1, miR34a, DKK, TBX5,
DCC) were determined of the methylation status using methylation-specific PCR in 70
paired NSCLC specimens and adjacent normal tissues.
CIMP positive is referred to having four or more than four synchronously
methylated genes per sample. Through our study, we tried to find out methylation
profiles in primary tumor samples and corresponding normal lung tissues, CpG island
methylator phenotype (CIMP) and clinicopathological correlation in NSCLC and
analysis of correlation of CIMP status and progression-free survival (PFS).
Thus, the results indicated that methylated alteration of multiple genes plays an
important role in NSCLC pathogenesis and insufficient evidence for an association of
CIMP status with survival prognosis of NSCLC warranted us to perform a further
confirmation.